CastleKnight Management’s Medifast MED Stock Holding History

CastleKnight Management’s Portfolio MED Stock Details MED Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-9,050	Closed	-$834K	–	336
2023 Q2	$834K	Hold	9,050	–	–	0.09%	148
2023 Q1	$938K	Hold	9,050	–	–	0.1%	139
2022 Q4	$1.04M	Hold	9,050	–	–	0.14%	96
2022 Q3	$981K	Buy	9,050 +1,250	+16%	+$179K	0.14%	92
2022 Q2	$1.41M	Buy	7,800 +4,400	+129%	+$787K	0.23%	75
2022 Q1	$581K	Buy	+3,400	New	+$641K	0.08%	161

Other funds holding MED

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Pacer Advisors Malvern, Pennsylvania $39.3B AUM 27.96% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

First Trust Advisors Wheaton, Illinois $170B AUM 46.21% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

CastleKnight Management's MED Position: Q3 2023 in Review

CastleKnight Management sold out of Medifast (MED) in Q3 2023, closing a stake of 9,050 shares — an estimated $834K sold.

CastleKnight Management first reported a position in MED in Q1 2022 and held it in 6 quarters. The position peaked at $1.41M in Q2 2022. 223 funds tracked by Wall St. Rank hold MED as of Q3 2023.

CastleKnight Management reported no remaining Medifast position as of Q3 2023 after selling out during the quarter.
CastleKnight Management sold 9,050 Medifast shares in Q3 2023, an estimated $834K.
CastleKnight Management first reported a position in Medifast in Q1 2022 and held it in 6 quarters.
CastleKnight Management's Medifast position peaked at $1.41M in Q2 2022.
223 funds tracked by Wall St. Rank held Medifast as of Q3 2023.

Based on CastleKnight Management's 13F filing for Q3 2023, filed 14 Nov 2023.